Skip to main content

Table 2 Descriptive characteristics of the study group (n = 70)

From: Comparison of five different popular scoring systems to predict nonsentinel lymph node status in patients with metastatic sentinel lymph nodes: a tertiary care center experience

Characteristics of patients n (%)
Age (years)
 ≤50 36 (51.4 %)
 >50 34 (48.6 %)
Pathologic tumor size (cm)
 ≤2 28 (40 %)
 2–5 40 (57.1 %)
 >5 2 (2.9 %)
Tumor type
 Invasive ductal carcinoma 60 (85.7 %)
 Invasive lobular carcinoma 6 (8.6 %)
 Other 4 (5.7 %)
Nuclear grade
 1 0
 2 34 (48.6 %)
 3 36 (51.4 %)
Localization of tumor
 Upper outer quadrant 22 (31.4 %)
 Upper inner quadrant 8 (11.4 %)
 Lower outer quadrant 6 (8.6 %)
 Lower İnner quadrant 4 (5.7 %)
 Central 5 (7.2 %)
 Unknown 25 (35.7 %)
Multifocality
 Yes 14 (20 %)
 No 56 (80 %)
Estrogen receptor
 Positive 54 (77.1 %)
 Negative 16 (22.9 %)
Progesterone receptor
 Positive 58 (82.9 %)
 Negative 12 (17.1 %)
c-erb B2 receptor
 Positive 17 (24.3 %)
 Negative 53 (75.7 %)
Lymphovascular invasion
 Yes 11 (15.7 %)
 No 59 (84.3 %)
Perineural invasion
 Yes 2 (2.8 %)
 No 68 (97.2 %)
Method of SLNB
 Isosulfan blue 53 (75.7 %)
 Tc99 m sulfur colloid 10 (14.3 %)
 Combined 7 (10 %)
Number of SLNs
 1 24 (34.2 %)
 2 16 (22.8 %)
 3 13 (18.6 %)
 >3 17 (24.3 %)
Number of positive SLN
 1 39 (55.7 %)
 2 20 (28.6 %)
 3 9 (12.8 %)
 >3 2 (2.9 %)
Proportion of involved SLNs among all SLNs, number of SLNs
 1 40 (57.1 %)
 0.75 5 (7.1 %)
 0.66 4 (5.7 %)
 0.50 8 (11.4 %)
 0.42 1 (1.4 %)
 0.40 1 (1.4 %)
 0.33 5 (7.1 %)
 0.28 1 (1.4 %)
 0.25 5 (7.1 %)
Micrometastases in SLNs
 Yes 13 (18.6 %)
 No 57 (81.4 %)
Extracapsular extansion
 Yes 6 (8.6 %)
 No 64 (91.4 %)
Additional non-SLN metastases
 Present 34 (48.6 %)
 Absent 36 (51.4 %)
Number of non-SLNs with additional metastases
 1 30/34 (88.2 %)
 2 2/34 (5.9 %)
 3 1/34 (2.9 %)
 >3 1/34 (2.9 %)
  1. SLNB sentinel lymph node biopsy, SLN sentinel lymph node